It is well known that uptake of nanodrugs in cancer cells involves adenosine triphosphate (ATP)-dependent uptake mechanisms (i.e., dynamin-dependent), such as macropinocytosis, clathrin-coated pits, caveolae and associated intracellular trafficking of drugs in cancer cells were significantly different from the trends observed in normal cells3–6. This evidence concerns the gene DNM1 and cancer.